Skip to Main Content

Paper Details

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Br J Cancer
19
2019
HDAC, HER2, HER2+, HER2-positive (HER2+) breast cancer, HER2-positive metastatic breast cancer, Human, Human epidermal growth factor 2, Neutropenia, breast cancer, cancer, cancer cells, diarrhoea, entinostat, hypokalaemia, lapatinib, metastatic breast cancer, neutropenia, patients, thrombocytopenia, trastuzumab, tumour
Author NameAffiliation
Bora LimThe University of Texas MD Anderson Cancer Center
Bora LimMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
Yu ShenThe University of Texas MD Anderson Cancer Center
Abenaa M BrewsterThe University of Texas MD Anderson Cancer Center
Powel H BrownThe University of Texas MD Anderson Cancer Center
Sharon H GiordanoThe University of Texas MD Anderson Cancer Center
Sharon H GiordanoThe University of Texas MD Anderson Cancer Center
Naoto T UenoThe University of Texas MD Anderson Cancer Center
Naoto T UenoMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center
  • 1 - 9

Datasets

Release 1.2